ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Crispr/Cas9 Platform Developed Maize Mutant Library Covering 800 Functional Genes with CRISPR/Cas9 Technology

By: IssueWire

New York City, New York Apr 1, 2023 (Issuewire.com) - Crispr/Cas9 platform, the division of Creative Biogene, is founded and managed by a group of experienced biotech scientists, the company aims to help customers simplify and accelerate biomolecule research and development projects, and bring reliable and affordable research services to the community. Creative Biogene has extensive experience in molecular biology, antibody engineering, and custom assay development. Recently, Creative Biogene announced the release of its maize mutant library to accelerate the development of improved crops.

Creative Biogene, a world-leading biotechnology company focusing on genome editing, has extensive experience in plant transformation, crop improvement, and breeding. Using the latest CRISPR/Cas9 technology, scientists at Creative Biogene have successfully achieved efficient gene editing in a variety of plants, including Arabidopsis, rice, tomato, corn, tobacco, wheat, soybean, etc. Based on an excellent platform, Creative Biogene is able to provide precise gene knockout maize, and all maize mutants have been verified at the genome level by PCR and sequencing.

As one of the most important food, feed, and fuel crops in agriculture, increasing the yield of maize (Zea mays) will help meet our food production needs beyond current forecasts. It usually takes 8-10 years to develop superior varieties through conventional breeding methods. The breeding process can be sped up by using a genome editing technology called CRISPR-Cas9, reducing the time needed to just 2-3 years. Creative Biogene's professional plant genome editing team used CRISPR/Cas9 technology to develop a maize mutant library covering about 800 functional genes. In addition, Creative Biogene uses gene editing to improve agronomic traits (e.g., plant grain yield, nutrient content, disease resistance) and accelerate crop domestication. 

The advantages of Creative Biogene's maize mutant lines include providing complete loss-of-function mutants (homozygous mutant lines), which are verified by Sanger sequencing. Approximately 800 pre-made corn mutant lines are also available for customer research to expedite the research process.

"Our maize mutant library covers homozygous, heterozygous, biallelic, and chimeric mutants created through CRISPR/Cas9 technology. Our prefabricated variant materials save you time and speed up the research process." said Marcia Brady, the marketing director of Creative Biogene, she also added, "In addition, we use the latest genome editing platform to provide genome-wide mutant library construction services for rice, Arabidopsis, tomato, tobacco, and other species."

About Creative Biogene

Creative Biogene, is a top-of-its-kind company that holds a leading position and is committed to accelerating the development of human science through biotechnology, offering innovative technologies, products, unique tools, and services for research discoveries and product development. With more than 10 years of experience and in-house experts, Creative Biogene has become a well-recognized industry leader to support researchers worldwide.

 

Media Contact

Creative Biogene


contact@creative-biogene.com

1-631-386-8241

Shirley, NY 11967, USA

https://www.creative-biogene.com/

Source :Creative Biogene

This article was originally published by IssueWire. Read the original article here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.